HOOKIPA Pharma Announces Pricing of Initial Public Offering
April 17 2019 - 10:49PM
HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class
of immunotherapeutics, targeting infectious diseases and cancers
based on its proprietary arenavirus platform, today announced the
pricing of its initial public offering of 6,000,000 shares of
common stock at a public offering price of $14.00 per share. In
addition, HOOKIPA has granted the underwriters a 30-day option to
purchase up to 900,000 additional shares of common stock at the
initial public offering price, less underwriting discounts and
commissions. The gross proceeds from the offering, before deducting
underwriting discounts and commissions and estimated offering
expenses, are expected to be $84 million, excluding any exercise of
the underwriters’ option to purchase additional shares.
HOOKIPA plans to use the offering proceeds to advance HB-101,
its lead product candidate in infectious diseases for the
prevention of cytomegalovirus infections, through completion of the
ongoing Phase 2 clinical trial, to advance HB-201 and HB-202, its
lead oncology product candidates for cancers caused by human
papilloma virus into and through completion of Phase 1 clinical
trials, as well as to advance HB-301, its product candidate in
metastatic, hormone-resistant prostate cancer into and through a
Phase 1 clinical trial. Furthermore, HOOKIPA intends to further
progress its earlier pipeline projects and ongoing research and
development activities as well as for working capital and other
general corporate purposes.
The shares are expected to begin trading on the Nasdaq Global
Select Market under the ticker symbol “HOOK” on Thursday, April 18,
2019. The offering is expected to close on April 23, 2019, subject
to customary closing conditions.
BofA Merrill Lynch, SVB Leerink, and RBC Capital Markets are
serving as joint book-running managers for the offering. Kempen is
acting as a co-manager for the offering.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission on April 17, 2019. The offering of these shares is being
made only by means of a prospectus. Copies of the final prospectus
relating to this offering, when available, may be obtained from
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department,
by email at dg.prospectus_request@baml.com or by phone at
1-800-294-1322; SVB Leerink LLC, Attention: Syndicate Department,
One Federal Street, 37th Floor, Boston, MA 02110, by telephone at
1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com;
or RBC Capital Markets, LLC, Attention: Equity Syndicate
Department, 200 Vesey Street, 8th Floor, New York, NY 10281, by
telephone at 1-877-822-4089 or by email at
equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About HOOKIPA HOOKIPA Pharma Inc. is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
For further information, please contact:
HOOKIPA Nina Waibel Head of Communications
Nina.Waibel@HookipaPharma.com
Media enquiries Sue Charles/ Ashley Tapp
Instinctif Partners Hookipa@Instinctif.com +44 (0)20 7457 2020
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024